

Fibrosis Program Patents

METHOD OF TREATING EARLY STAGE DUPUYTREN'S DISEASE

Country	Application No.	Date Filed	Status
Australia	2017248273	16/10/2018	Filed
Canada	3020327	05/10/2018	Filed
Europe	17779836	05/11/2018	Filed
Hong Kong	19128046	12/08/2019	Filed
U.S.	62/320,151	08/04/2016	Filed
U.S.	16/089,234	27/09/2018	Filed

METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING AN IL-33 ANTAGONIST

Country	Application No.	Date Filed	Status
Australia	2016226414	15/09/2017	Filed
Canada	2,978,449	29/02/2016	Filed
Europe	16759325	25/09/2017	Filed
Hong Kong	18107063.7	30/05/2018	Filed
U.S.	15/555,027	15/12/2017	Granted 10/12/2019 (US10500273B2)

METHOD OF TREATING A LOCALIZED FIBROTIC DISORDER USING A TNF RECEPTOR 2 ANTAGONIST

Country	Application No.	Date Filed	Status
Australia	2016226415	18/09/2017	Filed
Canada	2,978,431	29/02/2016	Filed
Europe	16759326.8	25/09/2017	Filed
Hong Kong	18107062.8	30/05/2018	Filed
U.S.	15/555,030	31/08/2017	Filed

Fibrosis Program Patents

METHOD OF TREATING OCULAR FIBROSIS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	62/722,263	24/08/2018	Filed

METHOD OF TREATING LOCALIZED FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	16/328,979	27/02/2019	Filed
Europe	17924768.9	01/04/2019	Filed

METHOD OF TREATING SYSTEMIC FIBROTIC DISORDERS USING AN IL-33/TNF BISPECIFIC ANTIBODY

Country	Application No.	Date Filed	Status
U.S.	16/329,013	27/02/2019	Filed
Europe	17847574.5	01/04/2019	Filed
Hong Kong	62020001194	09/01/2020	Filed

METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS INCLUDING DUPUYREN'S WITH ONE OR MORE SPECIFIC HUMAN MMP AND ATNF ANTAGONIST

Country	Application No.	Date Filed	Status
U.S.	61/845,366	11/07/2013	Filed

USES OF IL-33 RECEPTORS ANTAGONIST

Country	Application No.	Date Filed	Status
U.S.	62/127,157	02/03/2015	Filed

Fibrosis Program Patents (cont'd)

TREATMENT FOR DUPUYTREN'S DISEASE					
Country	Application No.	Date Filed/Granted	Status	Patent Number	Note
Australia	2011322482	06/07/2017	Granted	2,011,322,482	
Australia	2017204267	05/09/2019	Granted	2,017,204,267	
Canada	2,847,197	28/02/2014	Filed		
The European patent valid or being validated in:					
Europe	11779628.4	20/02/2019	Granted	E-1075071	Austria
Europe	11779628.4	12/02/2019	Granted	2,362,446	Belgium
Europe	11779628.4	14/02/2019	Granted	60 2011 054 785.2	Germany
Europe	11779628.4	07/03/2019	Granted	2,362,446	Finland
Europe	11779628.4	09/01/2019	Granted	2,362,446	France
Europe	11779628.4	07/03/2019	Granted	2,362,446	Iceland
Europe	11779628.4	02/01/2019	Granted	2362446-IE	Ireland
Europe	11779628.4	11/03/2019	Granted	502,019,000,019,925	Italy
Europe	11779628.4	12/02/2019	Granted	2,362,446	Netherlands
Europe	11779628.4	28/02/2019	Granted	2,362,446	Norway
Europe	11779628.4	11/03/2019	Filed		Spain
Europe	11779628.4	28/02/2019	Granted	2,362,446	Sweden
Europe	11779628.4	26/02/2019	Granted	2,362,446	Switzerland/Liechtenstein
Europe	11779628.4	21/12/2018	Granted	2,362,446	United Kingdom
Japan	2013-535462	16/09/2016	Granted	6004494	
U.S.	16/399,547	02/06/2020	Granted	10669334	

Fibrosis Program Patents (cont'd)

METHODS OF PREVENTION OR TREATMENT OF TRIGGERED INFLAMMATORY REACTIONS USING TNF ALPHA ANTAGONIST

Country	Application No.	Date Granted	Status	Patent Number	Note
Europe	11710004	03/06/2020	Granted	2,547,363	Austria
Europe	11710004	03/06/2020	Granted	2547363	Belgium
Europe	11710004	03/06/2020	Granted	2547363	Switzerland
Europe	11710004	03/06/2020	Granted	602,011,067,119	Germany
Europe	11710004	03/06/2020	Granted	DK/EP 2547363	Denmark
Europe	11710004	03/06/2020	Granted	2547363	Spain
Europe	11710004	03/06/2020	Granted	2547363	Finland
Europe	11710004	03/06/2020	Granted	2547363	France
Europe	11710004	03/06/2020	Granted	2547363	Ireland
Europe	11710004	03/06/2020	Granted	2547363	Italy
Europe	11710004	03/06/2020	Granted	2547363	Netherland
Europe	11710004	03/06/2020	Granted	2547363	Norway
Europe	11710004	03/06/2020	Granted	2547363	Sweden
Europe	11710004	03/06/2020	Granted	2547363	United Kingdom

METHOD FOR TREATMENT OF POST OPERATIVE COGNITIVE DYSFUNCTION

Country	Application No.	Grant Date	Status	Patent Number	Note
U.S.	13/579,555	12/04/2016	Granted	9,308,254	
Japan	2012-553396	24/06/2016	Granted	5,955,227	

SCA Program Patents

SCA: CYCLOHEXYL COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES

Country	Application No.	Date Filed/Granted	Status	Note
US2	10239848	26/03/2019	Granted	Claims directed to a method for treating obesity or a disease/disorder associated therewith by administration of a compound of the formula as defined in claim 1 – issued.
US3	11,149,014B2	19/10/2021	Granted	Claims directed to a method for treating pain or associated condition or symptom by administration of a compound of the formula as defined in claim 1
IL	248256	31/07/2018	Granted	Claims directed to a pharmaceutical composition for treatment of (i) obesity or a disease/disorder associated therewith; or (ii) abnormal food consumption or body weight, or a condition or symptom associated therewith, comprising a compound of the formula 1 as defined in claim 1
Europe	EP3134393 B1	09/12/2020	Granted	Claims directed to a pharmaceutical composition for use in the treatment of chronic pain. Valid in: Austria, Belgium, Germany, Finland, France, Iceland, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland/Liechtenstein and the United Kingdom.
CN	ZL201580020978.7	14/01/2020	Granted	This invention relates to phenyl substituted cyclohexenyl compounds, compositions comprising them and uses thereof for the preparation of medicaments as defined in claim 1
CA	CA2944837A1	26/10/2021	Granted	Claims directed to use of HU-435 or a salt thereof, e.g. the molecule salt thereof (HU-436), for the preparation of a pharmaceutical composition for treatment of chronic pain.

SCA: CANNABINOID DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION AND/OR PAIN AND/OR OBESITY

Country	Application No.	Date Filed/Granted	Status	Note
	PCT/IL2021/051398	24/11/2021	Filed	PCT filed via EPO, priority date 24 Nov, 2020

SCA: BIOACTIVE PHENOLATE IONIC COMPLEXES

Country	Application No.	Date Filed/Granted	Status	Note
	PCT/IL2021/05045	21/04/2021	Filed	PCT filed via EPO, priority date 22 Apr, 2020

a7nAChR Program Patents

a7nAChR				
Country	Date Filed/Granted	Status	Patent/Application Number	Note
US Grant	16/09/2014	Granted	US8835391B2	Alpha B-crystallin as a therapy for multiple sclerosis
US Grant	25/01/2011	Granted	US7875589B2	Alpha B-crystallin as a therapy for rheumatoid arthritis
Europe	06/01/2021	Granted	EP 3377178B1	Peptide for use in the treatment of medical conditions with inflammatory or autoimmune components
US Application	16/09/2019	Filed	US20180333451A1	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.
Canada	18/11/2016	Filed	3004908	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.
Japan	18/11/2016	Filed	2018-526196	B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components.